Condition
Graft-Versus-Host Disease(GVHD)
Total Trials
5
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (1)
P 2 (2)
Trial Status
Enrolling By Invitation1
Unknown1
Recruiting1
Not Yet Recruiting1
Withdrawn1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07570745Phase 2RecruitingPrimary
Low-Dose ATG/PTCy Plus Ivarmacitinib for aGVHD Prevention in Haplo-PBSCT From Parous Female Donors
NCT06905834Phase 2Not Yet Recruiting
Evaluation of Allogenic Mesenchymal Stem Cell (MSC) Injection Therapy for Refractory Graft-versus-Host Disease (GVHD) Unresponsive to Conventional Treatments
NCT07162688Phase 1Enrolling By InvitationPrimary
Effects of Omega-3 Fatty Acids on Acute Graft-versus-Host Disease After Allogeneic Stem Cell Transplantation.
NCT06598332Early Phase 1WithdrawnPrimary
5-Azacytidine With Steroids for Gastrointestinal GVHD (5-AZA FOR GVHD)
NCT02026934UnknownPrimary
CliniMACS® CD34+ Reagent System for Expanded Access Use
Showing all 5 trials